Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Pharma
  4. Pharma — Maj 2023

Pharma — Maj 2023

Planlagt Fastgjort Låst Flyttet Pharma
33 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • A Offline
    A Offline
    Aps_invest
    wrote on sidst redigeret af
    #24

    Lundbeck: Bestyrelsesmedlem køber aktier for knap 2 mio. kr.
    7:56
    Jakob Riis, der er bestyrelsesmedlem i Lundbeck, har købt aktier i medicinalselskabet for knap 2 mio. kr.

    Det oplyser Lundbeck i en insidermeddelelse mandag morgen.

    Bestyrelsesmedlemmet har købt 54.138 aktier for samlet 1.998.233,58 kr., svarende til en stykpris på 36,91 kr.

    Købet er dateret til 12. maj.

    Fredag blev B-aktien i Lundbeck handlet til 36,66 kr. efter et fald på 1,4 pct.

    .\˙ MarketWire

    1 Reply Last reply
    0
    • A Offline
      A Offline
      Aps_invest
      wrote on sidst redigeret af
      #25

      Novozymes får løftet sit kursmål til 520 kr. fra 510 kr. af finanshuset Bernstein, der gentager den positive anbefaling "outperform".

      1 Reply Last reply
      0
      • U Offline
        U Offline
        UlrikChristiansen8
        wrote on sidst redigeret af
        #26

        hvad synes folk om lundbeck?

        1 Reply Last reply
        0
        • P Offline
          P Offline
          ProinvestorNEWS
          wrote on sidst redigeret af
          #27

          Biogen : Canada Accepts New Drug Submission For Lecanemab As Treatment For Early Alzheimer's Disease https://www.proinvestor.com/investornyt/986031/biogen-canada-accepts-new-drug-submission-for-lecanemab-as-treatment-for-early-alzheimers-disease

          1 Reply Last reply
          0
          • Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktør
            wrote on sidst redigeret af
            #28

            FDA Approves AbbVie's Rinvoq As Once-Daily Pill For Crohn's Disease In Adults https://www.proinvestor.com/investornyt/988250/fda-approves-abbvies-rinvoq-as-once-daily-pill-for-crohns-disease-in-adults

            1 Reply Last reply
            0
            • Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktør
              wrote on sidst redigeret af
              #29

              Months after joining, Teva CEO pulls curtain back on strategy to return to growth https://firstwordpharma.com/story/5741789

              1 Reply Last reply
              0
              • Helge_LarsenPI-redaktørH Offline
                Helge_LarsenPI-redaktørH Offline
                Helge_LarsenPI-redaktør
                wrote on sidst redigeret af
                #30

                Lilly's peresolimab hits main goal in Phase II rheumatoid arthritis study https://www.proinvestor.com/boards/112684/

                1 Reply Last reply
                0
                • P Offline
                  P Offline
                  ProinvestorNEWS
                  wrote on sidst redigeret af
                  #31

                  Sanofi:Dupixent Phase 3 COPD Results Presented At ATS & Published In New England Journal Of Medicine https://www.proinvestor.com/investornyt/989207/sanofidupixent-phase-3-copd-results-presented-at-ats-amp-published-in-new-england-journal-of-medicine

                  1 Reply Last reply
                  0
                  • L Offline
                    L Offline
                    LP90
                    wrote on sidst redigeret af
                    #32

                    Godmorgen 🙂

                    1 Reply Last reply
                    0
                    • P Offline
                      P Offline
                      ProinvestorNEWS
                      wrote on sidst redigeret af
                      #33

                      Sandoz : EMA Accepts MAA For Proposed Biosimilar Denosumab https://www.proinvestor.com/investornyt/991161/sandoz-ema-accepts-maa-for-proposed-biosimilar-denosumab

                      1 Reply Last reply
                      0
                      • L Offline
                        L Offline
                        LP90
                        wrote on sidst redigeret af
                        #34

                        Godmorgen 🙂

                        1 Reply Last reply
                        0

                        Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                        Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                        With your input, this post could be even better 💗

                        Tilmeld Log ind
                        Svar
                        • Svar som emne
                        Login for at svare
                        • Ældste til nyeste
                        • Nyeste til ældste
                        • Most Votes


                        • Log ind

                        • Har du ikke en konto? Tilmeld

                        • Login or register to search.
                        Powered by NodeBB Contributors
                        • First post
                          Last post
                        0
                        • Kategorier
                        • Seneste
                        • Etiketter
                        • Populære
                        • Verden
                        • Bruger
                        • Grupper